Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 2/2016

01-02-2016 | Original Article

Priming hMSCs with a putative anti-cancer compound, myrtucommulone-a: a way to harness hMSC cytokine expression via modulating PI3K/Akt pathway?

Authors: Banu Iskender, Kenan Izgi, Cagri Sakalar, Halit Canatan

Published in: Tumor Biology | Issue 2/2016

Login to get access

Abstract

Tumour microenvironment is a key factor for cancer growth and metastasis. Tumour surrounding tissue is known to include high number of mesenchymal stem cells which have been thought to have a role in regulating cancer cell behaviour via paracrine signalling. Therefore, modulating human mesenchymal stem cell (hMSC) secretome is highly significant for controlling and treating disease. Since common therapeutic agents are known to enhance cancer resistance, there is a strong urge to define novel agents for developing cell-based therapies. In the present study, we aimed at investigating the effect of active compounds, myrtucommulone-A (MC-A) and thymoquinone (TQ), on hMSC cytokine expression. Our data revealed that MC-A treatment have significantly altered cytokine expression in hMSCs. Upon MC-A treatment, hMSCs decreased the expression levels of various cytokines including TNF-α, VEGF, IL-6, IL-8 and FGF-2. hMSC conditioned medium (CM) primed with MC-A decreased the proliferation, migration ability and clonogenicity of bladder cancer cells and breast cancer cells in comparison to non-primed hMSC medium and hMSC medium primed with TQ. To the best of our knowledge, this study is the first report showing the effects of active compounds, MC-A and TQ, on hMSCs and therefore valuable for highlighting the potential use of active compounds in combination with hMSCs for cell-based targeted cancer therapy.
Appendix
Available only for authorised users
Literature
1.
Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy. 2006;8:315–7.CrossRefPubMed
2.
Dorronsoro A, Fernández-Rueda J, Fechter K, Ferrin I, Salcedo JM, Jakobsson E, Trigueros C: Human mesenchymal stromal cell-mediated immunoregulation: mechanisms of action and clinical applications. Bone Marrow Res 2013;2013.
3.
Ramdasi S, Sarang S, Viswanathan C. Potential of mesenchymal stem cell based application in cancer. Int J Hematol Oncol Stem Cell Res. 2015;9:95–103.PubMedPubMedCentral
4.
Yu JM, Jun ES, Bae YC, Jung JS. Mesenchymal stem cells derived from human adipose tissues favor tumor cell growth in vivo. Stem Cells Dev. 2008;17:463–73.CrossRefPubMed
5.
Tian LL, Yue W, Zhu F, Li S, Li W. Human mesenchymal stem cells play a dual role on tumor cell growth in vitro and in vivo. J Cell Physiol. 2011;226:1860–7.CrossRefPubMed
6.
Luo J, Ok Lee S, Liang L, Huang CK, Li L, Wen S, et al. Infiltrating bone marrow mesenchymal stem cells increase prostate cancer stem cell population and metastatic ability via secreting cytokines to suppress androgen receptor signaling. Oncogene. 2014;33:2768–78.CrossRefPubMed
7.
Hou L, Wang X, Zhou Y, Ma H, Wang Z, He J, et al. Inhibitory effect and mechanism of mesenchymal stem cells on liver cancer cells. Tumour Biol. 2014;35:1239–50.CrossRefPubMed
8.
Atsuta I, Liu S, Miura Y, Akiyama K, Chen C, An Y, et al. Mesenchymal stem cells inhibit multiple myeloma cells via the Fas/Fas ligand pathway. Stem Cell Res Ther. 2013;4:111.CrossRefPubMedPubMedCentral
9.
Ho IA, Toh HC, Ng WH, Teo YL, Guo CM, Hui KM, et al. Human bone marrow-derived mesenchymal stem cells suppress human glioma growth through inhibition of angiogenesis. Stem Cells. 2013;31:146–55.CrossRefPubMed
10.
Lis R, Touboul C, Raynaud CM, Malek JA, Suhre K, Mirshahi M, et al. Mesenchymal cell interaction with ovarian cancer cells triggers pro-metastatic properties. PLoS One. 2012;7, e38340.CrossRefPubMedPubMedCentral
11.
Halpern JL, Kilbarger A, Lynch CC. Mesenchymal stem cells promote mammary cancer cell migration in vitro via the CXCR2 receptor. Cancer Lett. 2011;308:91–9.CrossRefPubMedPubMedCentral
12.
Zhao M, Sachs PC, Wang X, Dumur CI, Idowu MO, Robila V, et al. Mesenchymal stem cells in mammary adipose tissue stimulate progression of breast cancer resembling the basal-type. Cancer Biol Ther. 2012;13:782–92.CrossRefPubMedPubMedCentral
13.
Mandel K, Yang Y, Schambach A, Glage S, Otte A, Hass R. Mesenchymal stem cells directly interact with breast cancer cells and promote tumor cell growth in vitro and in vivo. Stem Cells Dev. 2013;22:3114–27.CrossRefPubMed
14.
Klopp AH, Gupta A, Spaeth E, Andreeff M, Marini F. Concise review: dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem Cells. 2011;29:11–9.CrossRefPubMed
15.
Scherzed A, Hackenberg S, Froelich K, Kessler M, Koehler C, Hagen R, et al. Bmsc enhance the survival of paclitaxel treated squamous cell carcinoma cells in vitro. Cancer Biol Ther. 2011;11:349–57.CrossRefPubMed
16.
Chen DR, Lu DY, Lin HY, Yeh WL. Mesenchymal stem cell-induced doxorubicin resistance in triple negative breast cancer. Biomed Res Int. 2014;2014:532161.PubMedPubMedCentral
17.
Müller H, Paul M, Hartmann D, Huch V, Blaesius D, Koeberle A, et al. Total synthesis of myrtucommulone a. Angew Chem Int Ed Engl. 2010;49:2045–9.CrossRefPubMed
18.
Iskender B, Izgi K, Karaca H, Canatan H: Myrtucommulone-a treatment decreases pluripotency- and multipotency-associated marker expression in bladder cancer cell line HTB-9. J Nat Med 2015;[Epub ahead of print].
19.
Izgi K, Iskender B, Jauch J, Sezen S, Cakir M, Charpentier M, Canatan H, Sakalar C: Myrtucommulone-a induces both extrinsic and intrinsic apoptotic pathways in cancer cells. J Biochem Mol Toxicol 2015;[Epub ahead of print].
20.
Abukhader MM. Thymoquinone in the clinical treatment of cancer: fact or fiction? Pharmacogn Rev. 2013;14:117–20.CrossRef
21.
Sakalar C, Yuruk M, Kaya T, Aytekin M, Kuk S, Canatan H. Pronounced transcriptional regulation of apoptotic and TNF-NF-kappa-b signaling genes during the course of thymoquinone mediated apoptosis in HeLa cells. Mol Cell Biochem. 2013;383:243–51.CrossRefPubMed
22.
Darakhshan S, Bidmeshki PA, Hosseinzadeh CA, Sisakhtnezhad S. Thymoquinone and its therapeutic potentials. Pharmacol Res. 2015;95-96C:138–58.CrossRef
23.
Solchaga LA, Penick KJ, Welter JF: Chondrogenic differentiation of bone marrow-derived mesenchymal stem cells: Tips and tricks. Methods Mol Biol 2011;698.
24.
Chen J, Crawford R, Chen C, Xiao Y. The key regulatory roles of the PI3K/Akt signaling pathway in the functionalities of mesenchymal stem cells and applications in tissue regeneration. Tissue Eng Part B Rev. 2013;19:516–28.CrossRefPubMed
25.
Barcellos-de-Souza P, Gori V, Bambi F, Chiarugi P. Tumor microenvironment: bone marrow-mesenchymal stem cells as key players. Biochim Biophys Acta. 1836;2013:321–35.
26.
Ye J, Wu D, Wu P, Chen Z, Huang J. The cancer stem cell niche: cross talk between cancer stem cells and their microenvironment. Tumour Biol. 2014;35:3945–51.CrossRefPubMed
27.
Xu Q, Wang L, Li H, Han Q, Li J, Qu X, et al. Mesenchymal stem cells play a potential role in regulating the establishment and maintenance of epithelial-mesenchymal transition in MCF7 human breast cancer cells by paracrine and induced autocrine TGF-β. Int J Oncol. 2012;41:959–68.PubMed
28.
Ye H, Cheng J, Tang Y, Liu Z, Xu C, Liu Y, et al. Human bone marrow-derived mesenchymal stem cells produced TGFbeta contributes to progression and metastasis of prostate cancer. Cancer Invest. 2012;30:513–8.CrossRefPubMed
29.
Di GH, Liu Y, Lu Y, Liu J, Wu C, Duan HF. IL-6 secreted from senescent mesenchymal stem cells promotes proliferation and migration of breast cancer cells. PLoS One. 2014;9, e113572.CrossRefPubMedPubMedCentral
30.
Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007;449:557–63.CrossRefPubMed
31.
Chen DR, Lu DY, Lin HY, Yeh WL: Mesenchymal stem cell-induced doxorubicin resistance in triple negative breast cancer. Biomed Res Int 2014;2014.
32.
Wang M, Cai J, Huang F, Zhu M, Zhang Q, Yang T, et al. Pre-treatment of human umbilical cord-derived mesenchymal stem cells with interleukin-6 abolishes their growth-promoting effect on gastric cancer cells. Int J Mol Med. 2015;35:367–75.PubMed
33.
De Luca A, Lamura L, Gallo M, Maffia V, Normanno N. Mesenchymal stem cell-derived interleukin-6 and vascular endothelial growth factor promote breast cancer cell migration. J Cell Biochem. 2012;113:3363–70.CrossRefPubMed
34.
Ding G, Wang L, Xu H, Xu Z, Feng C, Ding Q, et al. Mesenchymal stem cells in prostate cancer have higher expressions of SDF-1, CXCR4 and VEGF. Gen Physiol Biophys. 2013;32:245–50.CrossRefPubMed
35.
Tu B, Du L, Fan QM, Tang Z, Tang TT. STAT3 activation by IL-6 from mesenchymal stem cells promotes the proliferation and metastasis of osteosarcoma. Cancer Lett. 2012;325:80–8.CrossRefPubMed
36.
Lin JT, Wang JY, Chen MK, Chen HC, Chang TH, Su BW, et al. Colon cancer mesenchymal stem cells modulate the tumorigenicity of colon cancer through interleukin 6. Exp Cell Res. 2013;319:2216–29.CrossRefPubMed
37.
Huang F, Wang M, Yang T, Cai J, Zhang Q, Sun Z, et al. Gastric cancer-derived MSC-secreted PDGF-DD promotes gastric cancer progression. J Cancer Res Clin Oncol. 2014;140:1835–48.CrossRefPubMed
38.
Cheng J, Ye H, Liu Z, Xu C, Zhang Z, Liu Y, et al. Platelet-derived growth factor-bb accelerates prostate cancer growth by promoting the proliferation of mesenchymal stem cells. J Cell Biochem. 2013;114:1510–8.CrossRefPubMed
39.
Hogan NM, Joyce MR, Murphy JM, Barry FP, O'Brien T, Kerin MJ, et al. Impact of mesenchymal stem cell secreted PAI-1 on colon cancer cell migration and proliferation. Biochem Biophys Res Commun. 2013;435:574–9.CrossRefPubMed
40.
Moustakas A, Heldin CH. Induction of epithelial-mesenchymal transition by transforming growth factor β. Semin Cancer Biol. 2012;22:446–54.CrossRefPubMed
41.
Oyanagi J, Kojima N, Sato H, Higashi S, Kikuchi K, Sakai K, et al. Inhibition of transforming growth factor-β signaling potentiates tumor cell invasion into collagen matrix induced by fibroblast-derived hepatocyte growth factor. Exp Cell Res. 2014;326:267–79.CrossRefPubMed
42.
Daly RJ, Carrick N, Darbre PD. Progression to steroid autonomy is accompanied by altered sensitivity to growth factors in S115 mouse mammary tumour cells. J Steroid Biochem Mol Biol. 1995;54:21–9.CrossRefPubMed
43.
Rosendahl AH, Forsberg G. IGF-i and IGFBP-3 augment transforming growth factor-beta actions in human renal carcinoma cells. Kidney Int. 2006;70:1584–90.CrossRefPubMed
44.
Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappab activation. Nature. 2000;406:86–90.CrossRefPubMed
45.
Demarchi F, Bertoli C, Sandy P, Schneider C. Glycogen synthase kinase-3 beta regulates NF-kappa B1/p105 stability. J Biol Chem. 2003;278:39583–90.CrossRefPubMed
46.
47.
Graham JR, Tullai JW, Cooper GM. GSK-3 represses growth factor-inducible genes by inhibiting NF-kappaB in quiescent cells. J Biol Chem. 2010;285:4472–80.CrossRefPubMed
48.
Gong R, Rifai A, Ge Y, Chen S, Dworkin LD. Hepatocyte growth factor suppresses proinflammatory NFκB activation through GSK3β inactivation in renal tubular epithelial cells. J Biol Chem. 2008;283:7401–10.CrossRefPubMedPubMedCentral
49.
Taurin S, Sandbo N, Qin Y, Browning D, Dulin NO. Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase. J Biol Chem. 2006;281:9971–6.CrossRefPubMed
50.
Guha M, Mackman N. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J Biol Chem. 2002;277:32124–32.CrossRefPubMed
51.
Cherla RP, Lee SY, Mulder RA, Lee MS, Tesh VL. Shiga toxin 1-induced proinflammatory cytokine production is regulated by the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling pathway. Infect Immun. 2009;77:3919–31.CrossRefPubMedPubMedCentral
52.
Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471–84.CrossRefPubMed
53.
Weichhart T, Costantino G, Poglitsch M, Rosner M, Zeyda M, Stuhlmeier KM, et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity. 2008;29:565–77.CrossRefPubMed
54.
Haidinger M, Poglitsch M, Geyeregger R, Kasturi S, Zeyda M, Zlabinger GJ, et al. A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation. J Immunol. 2010;185:3919–31.CrossRefPubMed
55.
Chiang GG, Abraham RT. Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem. 2005;280:25485–90.CrossRefPubMed
56.
57.
Yonezawa K, Tokunaga C, Oshiro N, Yoshino K. Raptor, a binding partner of target of rapamycin. Biochem Biophys Res Commun. 2004;313:437–41.CrossRefPubMed
58.
Wang L, Harris TE, Roth RA, Lawrence JCJ. PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J Biol Chem. 2007;282:20036–44.CrossRefPubMed
Metadata
Title
Priming hMSCs with a putative anti-cancer compound, myrtucommulone-a: a way to harness hMSC cytokine expression via modulating PI3K/Akt pathway?
Authors
Banu Iskender
Kenan Izgi
Cagri Sakalar
Halit Canatan
Publication date
01-02-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3995-9

Other articles of this Issue 2/2016

Tumor Biology 2/2016 Go to the issue

Review

The roles of microRNAs in Wilms’ tumors

Original Article

Identification of expression quantitative trait loci of RPTOR for susceptibility to glioma

Review

Pseudogene-expressed RNAs: a new frontier in cancers

Original Article

Lipase member H frequently overexpressed in human esophageal adenocarcinomas

Original Article

RETRACTED ARTICLE: Targeted DNA methylation analysis explores association of adenocarcinoma and neuroendocrine epitypes with lung cancer

Original Article

The chemokine receptor CXCR7 is a critical regulator for the tumorigenesis and development of papillary thyroid carcinoma by inducing angiogenesis in vitro and in vivo
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits